Compare INLX & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | OTLK |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 38.7M |
| IPO Year | 2013 | 2016 |
| Metric | INLX | OTLK |
|---|---|---|
| Price | $7.67 | $0.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 888.0 | ★ 1.1M |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | $11,336.00 | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,726.70 |
| Revenue Next Year | $15.82 | $80.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.50 | $0.38 |
| 52 Week High | $15.72 | $3.39 |
| Indicator | INLX | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 43.02 |
| Support Level | $7.50 | $0.39 |
| Resistance Level | $8.29 | $0.46 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 25.00 | 65.86 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.